Annabel Suter

Jul 1, 2023 | biorxiv.org | Oliver Turnbull |Annabel Suter |Bora Guloglu |Charlotte M. Deane

New Results doi: https://doi.org/10.1101/2023.06.28.546839 AbstractAntibodies with lambda light chains (lambda-antibodies) are generally considered to be less developable than those with kappa light chains (kappa-antibodies), leading to substantial systematic biases in drug discovery pipelines. This has contributed to kappa dominance amongst clinical-stage therapeutics.

Jun 30, 2023 | biorxiv.org | Oliver Turnbull |Annabel Suter |Bora Guloglu |Charlotte M. Deane

New Results doi: https://doi.org/10.1101/2023.06.28.546839 AbstractAntibodies with lambda light chains (lambda-antibodies) are generally considered to be less developable than those with kappa light chains (kappa-antibodies), leading to substantial systematic biases in drug discovery pipelines. This has contributed to kappa dominance amongst clinical-stage therapeutics.